Edgewise Therapeutics Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ null, 44.78, 83.11, 281.97, 420.42 ], "ebit_estimate": [ -227.4, -218, -235.38, -165.41, -83.89 ], "ebitda_estimate": [ -221.9, -194.94, -261.32, -235.95, 215.49 ], "net_income_estimate": [ -59.53, -184.74, -208.19, -92.55, 2.03 ], "per_share_eps_estimate": [ -1.96, -1.75, -1.15, -1.46, 0.23 ], "eps_nri_estimate": [ -1.96, -1.66, -1.66, -1.77, -0.06 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null ], "pretax_income_estimate": [ -214.03, -179.71, -204.43, -95.55, -78.47 ], "operating_cash_flow_per_share_estimate": [ -3.48, -0.6, -1.32, null, null ], "roa_estimate": [ 95.1, -5.6, -12.5, null, null ], "roe_estimate": [ 98.7, -5.8, -12.9, null, null ], "gross_margin_estimate": [ null, 92.67, 90.33, 90.33, 90.33 ], "operating_cash_flow_estimate": [ -372.77, -64.27, -141.39, null, null ], "pettm_estimate": [ 0, 0, 0, 0, 200.04 ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": 11.02, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -5.95, "future_ebitda_estimate_growth": -8.73, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ null, null, null, null, null, 68.33, 5.91 ], "ebit_estimate": [ -55.3, -57.85, -58.54, -64.17, -69.71, -5.38, -72.91 ], "ebitda_estimate": [ -54.83, -53.84, -58.53, -59.17, -63.77, -66.4, -69.08 ], "net_income_estimate": [ -51.86, -55.71, -53.97, -56.4, -60.11, 4.17, -63.4 ], "per_share_eps_estimate": [ -0.48, -0.51, -0.5, -0.52, -0.55, 0.05, -0.58 ], "eps_nri_estimate": [ -0.47, -0.51, -0.5, -0.48, -0.55, 0.05, -0.58 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ -52.34, -56.39, -54.1, -56.38, -60.11, 4.17, -63.4 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null ], "gross_margin_estimate": [ null, null, null, null, null, 90, 89 ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": 11.02, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -5.95, "future_ebitda_estimate_growth": -8.73, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }